689 related articles for article (PubMed ID: 28923239)
1. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
2. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.
Wu Z; Spencer LG; Banya W; Westoby J; Tudor VA; Rivera-Ortega P; Chaudhuri N; Jakupovic I; Patel B; Thillai M; West A; Wijsenbeek M; Maher TM; Smith JA; Molyneaux PL
Lancet Respir Med; 2024 Apr; 12(4):273-280. PubMed ID: 38237620
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
[TBL] [Abstract][Full Text] [Related]
7. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).
Martinez FJ; Wijsenbeek MS; Raghu G; Flaherty KR; Maher TM; Wuyts WA; Kreuter M; Kolb M; Chambers DC; Fogarty C; Mogulkoc N; Tutuncu AS; Richeldi L
Am J Respir Crit Care Med; 2022 May; 205(9):1084-1092. PubMed ID: 35050837
[No Abstract] [Full Text] [Related]
8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
10. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
[TBL] [Abstract][Full Text] [Related]
11. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
Maher TM; Simpson JK; Porter JC; Wilson FJ; Chan R; Eames R; Cui Y; Siederer S; Parry S; Kenny J; Slack RJ; Sahota J; Paul L; Saunders P; Molyneaux PL; Lukey PT; Rizzo G; Searle GE; Marshall RP; Saleem A; Kang'ombe AR; Fairman D; Fahy WA; Vahdati-Bolouri M
Respir Res; 2020 Mar; 21(1):75. PubMed ID: 32216814
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
13. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
[TBL] [Abstract][Full Text] [Related]
14. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
17. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
